Dynavax Technologies Corporation (DVAX)
USD 12.77
(-1.01%)
USD 12.77
(-1.01%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 256.91 Million USD | -0.42% |
| 2022 | 258.01 Million USD | 0.24% |
| 2021 | 257.38 Million USD | 18.15% |
| 2020 | 217.84 Million USD | 0.65% |
| 2019 | 216.44 Million USD | 114.58% |
| 2018 | 100.87 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 9.55 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 12.81 Million USD | 8.73% |
| 2010 | 11.78 Million USD | 26.12% |
| 2009 | 9.34 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 256.1 Million USD | -0.32% |
| 2024 Q2 | 255.28 Million USD | -0.32% |
| 2023 Q3 | 253.09 Million USD | -1.84% |
| 2023 Q4 | 256.91 Million USD | 1.51% |
| 2023 Q2 | 257.82 Million USD | 1.51% |
| 2023 FY | 256.91 Million USD | -0.42% |
| 2023 Q1 | 253.98 Million USD | -1.56% |
| 2022 Q1 | 257.98 Million USD | 0.23% |
| 2022 Q3 | 257.81 Million USD | 0.03% |
| 2022 Q4 | 258.01 Million USD | 0.08% |
| 2022 Q2 | 257.74 Million USD | -0.09% |
| 2022 FY | 258.01 Million USD | 0.24% |
| 2021 Q2 | 256.34 Million USD | 18.11% |
| 2021 FY | 257.38 Million USD | 18.15% |
| 2021 Q1 | 217.04 Million USD | -0.37% |
| 2021 Q4 | 257.38 Million USD | -0.25% |
| 2021 Q3 | 258.04 Million USD | 0.66% |
| 2020 Q1 | 219.5 Million USD | 1.41% |
| 2020 Q4 | 217.84 Million USD | -0.25% |
| 2020 Q2 | 218.93 Million USD | -0.26% |
| 2020 Q3 | 218.4 Million USD | -0.24% |
| 2020 FY | 217.84 Million USD | 0.65% |
| 2019 Q3 | 214.57 Million USD | 1.56% |
| 2019 FY | 216.44 Million USD | 114.58% |
| 2019 Q1 | 210.74 Million USD | 108.93% |
| 2019 Q2 | 211.27 Million USD | 0.25% |
| 2019 Q4 | 216.44 Million USD | 0.87% |
| 2018 Q4 | 100.87 Million USD | 0.55% |
| 2018 Q2 | 99.77 Million USD | 0.54% |
| 2018 Q1 | 99.23 Million USD | 0.0% |
| 2018 FY | 100.87 Million USD | 0.0% |
| 2018 Q3 | 100.31 Million USD | 0.55% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q1 | 9.5 Million USD | -0.54% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q2 | 9.45 Million USD | -0.5% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | 9.55 Million USD | 0.0% |
| 2014 FY | 9.55 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q2 | 13.9 Million USD | 4.1% |
| 2012 Q3 | 14.45 Million USD | 3.93% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q1 | 13.35 Million USD | 4.27% |
| 2012 FY | - USD | -100.0% |
| 2011 Q3 | 12.34 Million USD | -3.08% |
| 2011 FY | 12.81 Million USD | 8.73% |
| 2011 Q1 | 11.4 Million USD | -3.18% |
| 2011 Q2 | 12.73 Million USD | 11.63% |
| 2011 Q4 | 12.81 Million USD | 3.79% |
| 2010 FY | 11.78 Million USD | 26.12% |
| 2010 Q2 | 13.3 Million USD | 3.51% |
| 2010 Q1 | 12.85 Million USD | 37.55% |
| 2010 Q3 | 11.48 Million USD | -13.66% |
| 2010 Q4 | 11.78 Million USD | 2.59% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 9.34 Million USD | 0.0% |
| 2009 Q4 | 9.34 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -1294.114% |
| Harrow Health, Inc. | 190.5 Million USD | -34.862% |
| Biofrontera Inc. | 5.39 Million USD | -4658.548% |
| DURECT Corporation | 20.74 Million USD | -1138.378% |
| Cronos Group Inc. | 2.53 Million USD | -10014.971% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 64.095% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -607.304% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -21802.19% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Radius Health, Inc. | 365.31 Million USD | 29.673% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -4586.111% |
| ProPhase Labs, Inc. | 21.38 Million USD | -1101.656% |
| Phibro Animal Health Corporation | 525.45 Million USD | 51.107% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -9604.188% |
| Procaps Group S.A. | 285.93 Million USD | 10.15% |
| Alvotech | 1.07 Billion USD | 76.112% |
| TherapeuticsMD, Inc. | 8 Million USD | -3109.419% |
| Rockwell Medical, Inc. | 13.43 Million USD | -1811.705% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -38962.194% |
| Alpha Teknova, Inc. | 30.45 Million USD | -743.503% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -1416.791% |
| SCYNEXIS, Inc. | 15.08 Million USD | -1603.674% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -1598.156% |
| Theratechnologies Inc. | 58.96 Million USD | -335.684% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 18.525% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -42155.592% |
| Safety Shot Inc | 1.54 Million USD | -16486.076% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -518.667% |
| SIGA Technologies, Inc. | 1.46 Million USD | -17448.663% |
| Tilray Brands, Inc. | 387.31 Million USD | 33.668% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -97.08% |
| Viatris Inc. | 18.12 Billion USD | 98.582% |
| PetIQ, Inc. | 468.3 Million USD | 45.139% |
| OptiNose, Inc. | 131.74 Million USD | -95.003% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 40.029% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -38962.194% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -115.259% |
| Alimera Sciences, Inc. | 67.39 Million USD | -281.184% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 61.898% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 40.91 Million USD | -527.967% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -23520.062% |
| Cosmos Health Inc. | 12.42 Million USD | -1967.893% |
| Journey Medical Corporation | 17.73 Million USD | -1349.036% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -3004.104% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -12210.206% |
| Embecta Corp. | 1.63 Billion USD | 84.32% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -429471.789% |
| Procaps Group, S.A. | 285.93 Million USD | 10.15% |
| PainReform Ltd. | 86 Thousand USD | -298637.209% |
| Incannex Healthcare Limited | 373 Thousand USD | -68777.748% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -24767.9% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -626.074% |
| Shineco, Inc. | 29.65 Million USD | -766.301% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 56.161% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -159.977% |
| Alvotech | 1.07 Billion USD | 76.112% |
| Hempacco Co., Inc. | 13.72 Million USD | -1771.936% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -311.286% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 58.357% |
| Bright Green Corporation | 1.85 Million USD | -13773.872% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 52.507% |
| Kamada Ltd. | 8.74 Million USD | -2836.5% |
| Indivior PLC | 281.6 Million USD | 8.767% |
| Evoke Pharma, Inc. | 5 Million USD | -5038.28% |
| Flora Growth Corp. | 3.67 Million USD | -6896.569% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -24767.9% |
| Evolus, Inc. | 126.54 Million USD | -103.02% |
| HUTCHMED (China) Limited | 86.13 Million USD | -198.283% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 58.804% |
| Akanda Corp. | 3.99 Million USD | -6324.792% |